Manufacturer asserts that because the vaccine has been modified and no longer able to produce infection, it should be able to be produced on U.S. mainland.
July 23 webinar will be a continuation of immunology webinar presented in May.
U.S. experts say conclusions from swine influenza study in China lack context.
Ingelvac CSF MLV will be produced by company's Taizhou plant, and it is expected to be commercialized in early 2021.
Technology will allow foot-and-mouth disease vaccine manufacturing in the United States because it does not require the use of live FMDV for vaccine production.
Vaccine from Harbin Veterinary Research Institute has been field tested on 3,000 hogs.
This type of vaccine will also enable the differentiation of infected animals from those that have received a vaccine.
Pirbright scientists will measure the level of antibodies produced after vaccination of pigs and assess whether the antibodies can block SARS-CoV-2 from infecting cells.
The funding ensures the U.S. has tools to address disease risks including African swine fever and foot-and-mouth disease.
Collaboration seeks to develop effective gene-based, T-cell directed vaccines for economically significant swine diseases.